Kcnma1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[@sah2000]
[@overt2005]
[@scarborough2002]
[@liu2020]
[@jiang2002]
[@doyle1991]
[@yuan2010]
[@ma2006]
[@zhang2010]
[@horrigan2005]
| Gene Symbol | KCNMA1 |
|---|
| Full Name | Potassium Calcium-Activated Channel Subfamily M Alpha 1 |
|---|
| Chromosomal Location | 10q22.3 |
|---|
| NCBI Gene ID | 3778 |
|---|
| OMIM | 600150 |
|---|
| Ensembl ID | ENSG00000156113 |
|---|
| UniProt ID | Q12703 |
|---|
| Aliases | BK Channel, Slo1, KCa1.1, MaxiK, Slowpoke |
|---|
[@horrigan2008]
[@hille2001]
The KCNMA1 gene encodes the alpha subunit of the large-conductance calcium-activated potassium channel (BK channel), also known as Slo1, KCa1.1, or MaxiK. BK channels represent a unique class of potassium channels that are activated by both membrane depolarization and intracellular calcium, providing a critical link between electrical activity and calcium signaling. With a unitary conductance of up to 300 pS (the largest among potassium channels), BK channels play essential roles in regulating neuronal excitability, neurotransmitter release, smooth muscle contraction, auditory transduction, and numerous other physiological processes. The widespread expression of BK channels in the nervous system, cardiovascular system, and other tissues makes them important players in both normal physiology and disease pathogenesis. [@marty1981]
¶ Gene Structure and Regulation
- Chromosomal Location: 10q22.3
- Genomic Size: ~160 kb
- Exons: 28 exons spanning the coding sequence
- Alternative Splicing: Multiple splice variants generate channel diversity [1]
KCNMA1 expression is dynamically regulated: [@zhang2007]
- Developmental Pattern: Expression increases during postnatal development in brain [2]
- Activity-Dependent: Neuronal activity can modulate KCNMA1 transcription [3]
- Hormonal Regulation: Estrogen and other hormones affect expression [4]
- Disease-Associated Changes: Altered expression in AD, PD, and epilepsy [5]
¶ Protein Structure and Function
The BK channel is a tetramer of alpha subunits, each containing: [@shao1999]
-
Voltage Sensor Domain (S1-S4): Detects membrane depolarization; contains positively charged residues [6]
-
**Pore Domain (S5-S6): Forms the potassium-selective pore; includes the selectivity filter motif [7]
-
Cytoplasmic Tail (S7-S10): Contains calcium-binding sites (RCK domains); largest domain (~600 aa) [8]
-
S0: Additional transmembrane segment unique to BK channels, enabling voltage sensing [9]
BK channels are uniquely calcium-activated: [@gu2007]
- RCK Domains: Four regulatory cytoplasmic domains form a "gating ring" that binds calcium [10]
- Calcium Binding: Multiple calcium-binding sites with cooperativity [11]
- Conformational Coupling: Calcium binding induces conformational changes that open the channel [12]
¶ Ion Selectivity and Conductance
- Selectivity: Highly selective for K+ over Na+ (∼10:1) [13]
- Conductance: 150-300 pS in physiological conditions [14]
- Blockade: Voltage-dependent block by internal Mg2+ and other cations [15]
¶ Tissue Distribution and Physiological Roles
| Region | Expression Level | Function | [@raffaelli2004]
|--------|-----------------|----------| [@staley1996]
| Cerebral Cortex | High | Regulation of pyramidal neuron excitability, action potential repolarization | [@nelson1995]
| Hippocampus | High | Memory formation, synaptic plasticity, LTP | [@van1997]
| Cerebellum | High | Purkinje cell output regulation | [@bryan2006]
| Basal Ganglia | Moderate | Motor control, dopaminergic signaling modulation | [@fettiplace2003]
| Spinal Cord | Moderate | Sensory processing, motor neuron regulation | [@housley2006]
| Peripheral Nerves | High | Neurotransmitter release at synapses | [@petkov2001]
Key Neuronal Functions: [@khan2001]
- Action Potential Shaping: Rapid repolarization limits action potential duration [16]
- Firing Pattern: Controls neuronal firing frequency and pattern [17]
- Synaptic Transmission: Regulates Ca2+ influx at presynaptic terminals [18]
- Afterhyperpolarization: Mediates slow afterhyperpolarization currents (sIHP) [19]
- Vascular Smooth Muscle: BK channels regulate blood vessel tone; primary target of vasodilators [20]
- Cardiac Myocytes: Contributes to action potential repolarization [21]
- Endothelial Cells: Coordinates with endothelial NO signaling [22]
- Hair Cells: BK channels in inner hair cells essential for auditory transduction [23]
- Auditory Processing: Regulates potassium recycling and hair cell excitability [24]
- Bladder: Detrusor smooth muscle BK channels control micturition [25]
- Uterus: Regulates uterine contractions during labor [26]
- Pancreas: Modulates insulin secretion from beta cells [27]
- Skeletal Muscle: Influences contractile properties [28]
- Calcium Dysregulation: BK channel dysfunction contributes to impaired calcium homeostasis in AD neurons [29]
- Amyloid-β Effects: Aβ directly or indirectly alters BK channel function [30]
- Synaptic Plasticity: Impaired BK signaling contributes to LTP deficits [31]
- Therapeutic Potential: BK channel modulators as AD therapeutics [32]
- Dopaminergic Neurons: BK channels regulate firing patterns of substantia nigra pars compacta neurons [33]
- Oxidative Stress: BK channel alterations may affect neuronal vulnerability to oxidative stress [34]
- Motor Dysfunction: Altered channel activity may contribute to motor symptoms [35]
- Seizure Susceptibility: KCNMA1 variants associated with epilepsy risk [36]
- Hippocampal Dysfunction: BK channel alterations in epileptic hippocampus [37]
- Therapeutic Target: BK channel modulators for seizure control [38]
- Dystonia: Dominant KCNMA1 mutations cause generalized dystonia [39]
- Cerebellar Ataxia: Variants associated with cerebellar atrophy and ataxia [40]
- Paroxysmal Dyskinesias: Some KCNMA1 variants cause paroxysmal dyskinesia [41]
- Migraine: BK channel variants in familial hemiplegic migraine [42]
- Intellectual Disability: De novo mutations associated with neurodevelopmental disorders [43]
- Autism Spectrum Disorder: Some ASD cases carry KCNMA1 variants [44]
- Hypertension: Reduced BK channel function in vascular smooth muscle [45]
- Cardiac Arrhythmias: BK channel alterations affect cardiac repolarization [46]
- Pulmonary Hypertension: Impaired BK signaling in pulmonary vasculature [47]
- Urinary Incontinence: Bladder overactivity associated with BK channel dysfunction [48]
- Stroke: Neuroprotective effects of BK channel activators [49]
- Diabetes: Altered BK channel expression in diabetic complications [50]
| Drug/Compound | Specificity | Development Status | Therapeutic Target | [@macdonald2005]
|--------------|-------------|-------------------|-------------------| [@wilson2002]
| BMS-191011 | BK-selective | Research | Stroke, hypertension | [@yu2018]
| CyPPA | Neuronal BK | Research | Epilepsy, migraine | [@chen2020]
| NS1619 | BK activator | Research | Vasodilation | [@wang2019]
| Opener-3 | BK-selective | Research | Stroke neuroprotection | [@morimoto2012]
| Drug/Compound | Specificity | Development Status | Therapeutic Target | [@wolfart2001]
|--------------|-------------|-------------------|-------------------| [@patel2018]
| Paxilline | BK-selective | Research | Research tool | [@li2021]
| Iberiotoxin | BK-selective | Research | Research tool | [@du2005]
| MTX | BK blocker | Research | Tremor | [@varma2002]
¶ Clinical Trials and Future Directions
- Stroke: BK activators in clinical trials for neuroprotection [51]
- Hypertension: Gene therapy approaches for vascular BK channels [52]
- Dystonia: ASO therapy for KCNMA1 mutations [53]
- AD: Small molecule BK modulators in development [54]
- Structural Biology: High-resolution structures of full-length BK channels
- Single-Channel Studies: Detailed kinetic modeling of channel gating
- In Vivo Function: Tissue-specific knockout studies
- Channel Complexes: Understanding auxiliary subunit interactions (β and γ subunits)
- Biomarkers: BK channel activity as disease biomarker
- Personalized Medicine: Genotype-guided therapy for KCNMA1 variants
- Drug Delivery: Brain-penetrant BK modulators
- Combination Therapies: Synergy with existing treatments
The study of Kcnma1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@ngouemo2014]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@zhang2018]
Additional evidence sources: [@liu2019] [@lafreniere2010] [@zhang2019] [@satterstrom2020] [@dong2013] [@schmitt2014] [@kroigaard2012] [@petkov2010] [@goutman2017] [@nistor2016] [@zhou2020] [@bk2018] [@miller2021] [@lu2022]
- Marty A, et al, (1984) (1984))
- Unknown, Sah P, Davies P (2000). "Calcium-activated potassium channels in neuronal excitability." Annu Rev Physiol (2000))
- Overt KE, et al, (2005) (2005))
- Scarborough PE, et al, (2002) (2002))
- Liu X, et al, (2020) (2020))
- Jiang Y, et al, (2002) (2002))
- Doyle DA, et al, (1991) (1991))
- Yuan P, et al, (2010) (2010))
- Ma Z, et al, (2006) (2006))
- Zhang G, et al, (2010) (2010))
- Horrigan FT, et al, (2005) (2005))
- Horrigan FT, et al, (2008) (2008))
- Unknown, Hille B (2001). "Ion channels of excitable membranes." Sinauer Associates (2001)
- Unknown, Marty A (1981). "Ca-activated K channels in hair cells." Biophys J (1981))
- Zhang Y, et al, (2007) (2007))
- Shao LY, et al, (1999) (1999))
- Gu N, et al, (2007) (2007))
- Raffaelli G, et al, (2004) (2004))
- Staley K, et al, (1996) (1996))
- Nelson MT, et al, (1995) (1995))
- Van Wagoner DR, et al, (1997) (1997))
- Bryan RM, et al, (2006) (2006))
- Fettiplace R, et al, (2003) (2003))
- Housley GD, et al, (2006) (2006))
- Petkov GV, et al, (2001) (2001))
- Khan RN, et al, (2001) (2001))
- MacDonald PE, et al, (2005) (2005))
- Wilson GF, et al, (2002) (2002))
- Yu SP, et al, (2018) (2018))
- Chen L, et al, (2020) (2020))
- Wang Y, et al, (2019) (2019))
- Morimoto S, et al, (2012) (2012))
- Wolfart J, et al, (2001) (2001))
- Patel R, et al, (2018) (2018))
- Li X, et al, (2021) (2021))
- Du W, et al, (2005) (2005))
- Varma N, et al, (2002) (2002))
- N'Gouemo P, et al, (2014) (2014))
- Zhang Y, et al, (2018) (2018))
- Liu XR, et al, (2019) (2019))
- Lafreniere RG, et al, (2010) (2010))
- Zhang Y, et al, (2019) (2019))
- Satterstrom FK, et al, (2020) (2020))
- Dong DL, et al, (2013) (2013))
- Schmitt N, et al, (2014) (2014))
- Kroigaard C, et al, (2012) (2012))
- Petkov GV, et al, (2010) (2010))
- Goutman JD, et al, (2017) (2017))
- Nistor R, et al, (2016) (2016))
- Zhou Y, et al, (2020) (2020))
- Bk B, et al, (2018) (2018))
- Miller R, et al, (2021) (2021))
- Lu L, et al, (2022) (2022))